% | $
Quotes you view appear here for quick access.

Oncolytics Biotech, Inc. Message Board

  • cancer_free_since_94 cancer_free_since_94 Jan 24, 2006 4:17 AM Flag

    News Release

    Here it is:

    Oncolytics Biotech Inc.'s Research Collaborators to Present Phase I Combination REOLYSIN(R)/Radiation Clinical Trial Data at AACR Conference
    Tuesday January 24, 2:01 am ET

    CALGARY, Jan. 24 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that an oral presentation covering preliminary results of its Phase I combination REOLYSIN�/radiation clinical trial will be made at the American Association of Cancer Researchers (AACR) annual meeting, to be held April 1-5 in Washington, D.C. The presentation, entitled "Phase I trial of intratumoral administration of reovirus type 3 (Reolysin) in combination with radiation in patients with advanced malignancies" will be delivered by Principal Investigator Dr. Kevin J. Harrington of the Targeted Therapy Laboratory, The Institute of Cancer Research, Cancer Research UK Centre for Cell and Molecular Biology and Honorary Consultant in Clinical Oncology at The Royal Marsden NHS Foundation Trust, London, UK.

    Stay long & strong...


    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Wow - as soon as April???

      The way things are progressing, I am sure my grandkids will live to see Reolysin released - and my kids are only 6.

    • I see that, sorry. It was that the statement did not sound like bio_tex that caught my eye. Should have known.


    • I believe that ONC's future could very well be determined by the "final" results that come out uf this trial. For one thing, this trial is in Europe and the trials there are much more advanced than their US counterparts. Secondly, and most importantly, anecdotal observations from the reo/rad patent (based on results from the original phase 1 trial) suggested that the combination was the most efficacious in solid tumors. However, the results being presented at the conference could be just as devastating to ONC's future if they don't live up to expectations.Also, these results are "preliminary" and still over 2 months away.

    • I don't think DR. Harrington would attend a conference to tell his peers that reolysin does not work. Everything points to a huge success of reolysin: All the news releases in the last two months, the new trials being prepared, the interest shown by new investors, the possibility of a partnership, etc.This time , we can expect a nice pop up of the share price and a new and solid higher support price.

      • 2 Replies to lafrance_paul
      • <I don't think DR. Harrington would attend a conference to tell his peers that reolysin does not work.>

        Your comment makes it clear that you really don't understand how science works. Dr. Harrington is presenting the results of his or her research. It could show that Reolysin is fabulous, interesting, or of little value as an anti-cancer agent but he or she would still present the data.

        I am happy that we will get to see some data on Reolyisn plus radiation since that might be more efficacious than Reolysin alone. But one should never assume that the data will be positive simply because it is being presented. Of course I am hoping the data will be fabulous but we will see. I hope that this clears things up for you.


    • AACR = good
      Preliminary results = good
      oral presentation = good

      no reference to this being a "proof-of-concept" = good

      what are the results = ???

      if and when PII = ??? and well again the scambags pumping ONC yesterday seem to be way off.

0.33-0.02(-5.71%)Nov 4 4:00 PMEST